INTRODUCTION: Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer’s disease (AD). Its association with incident AD is unclear.
